ClinicalTrials.gg
RecruitingNCT07570940Updated Nov 19, 2026

A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

A Phase 4 interventional study of Liposomal bupivacaine and Placebo in Coronary Artery Disease and Atrial Fibrillation, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Coronary Artery Disease by Mayo Clinic — 3 open to participants now, 3 under way, none of them phase 3. Coronary Artery Disease · Mayo Clinic.

Planned enrollment
2nd of 15
450 · median 120
Started
2026
the only one that year
Phase 4
2 of 23
1 open now
Registered
23rd of 23
by date

Among the 23 studies in Coronary Artery Disease by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 4, and was the 23rd registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

3 of the 23 studies in Coronary Artery Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is assess the incidence of postoperative atrial fibrillation (POAF) within one week of surgery in patients who receive pre-surgical stellate ganglion blockade with liposomal bupivacaine, compared to those receiving a saline placebo, using continuous electrocardiographic monitoring via wearable ECG devices.

03

Conditions studied

  • Coronary Artery Disease
  • Atrial Fibrillation
04

Who can participate

The criteria were revised on the registry on Nov 19, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. Robotic CABG procedures are allowed.
  • Cases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if CABG is listed as the primary intervention with other procedures noted as possible additional interventions.
  • Cases will remain eligible if left atrial appendage ligation is concomitantly listed with the CABG.

Exclusion criteria

Exclusion criteria:

  • History of Permanent atrial fibrillation (paroxysmal, persistent or permanent),
  • Mechanical circulatory support implant or explant
  • Heart and/or lung transplant patients
  • Active infection/sepsis
  • Pre-operative anti-arrhythmic use (aside from beta-blockers).
  • MAZE procedures, pulmonary vein isolation or cryotherapy will exclude patients if concomitantly listed with the CABG.
  • Participant has a known allergy to adhesives or hydrogels.
  • Participant has a visible skin injury or broken skin at the location for study device placement.
  • Participant does not have the competency to wear the device for the prescribed patching period.
  • Participant has a neuro-stimulator, as it may disrupt the quality of data.
  • Participants who are pregnant. In accordance with Mayo Clinic's standard cardiac surgery protocol, all women of undergo routine preoperative pregnancy testing. Pregnancy status will therefore be confirmed prior to enrollment. Any participant with a positive pregnancy test will be deemed ineligible and will not be enrolled in the study.
  • Participants who lack the capacity to provide will not be approached or enrolled in this study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Stellate ganglion block using liposomal bupivacaine

    10 mL of liposomal bupivacaine 133 mg (133 mg/10 ml or 1.33%)

    Drug: Liposomal bupivacaine

  • Placebo comparator
    Sham block using saline placebo

    10 mL of saline placebo injected in the plane of the right stellate ganglion

    Drug: Placebo

Interventions

  • Patients undergoing isolated coronary artery bypass grafting will receive a stellate ganglion block using liposomal bupivacaine prior to surgery

  • DrugPlacebo

    Patients undergoing isolated coronary artery bypass grafting will receive a saline placebo injection to the stellate ganglion prior to surgery

06

What researchers measure

Primary outcomes

  1. Incidence of new-onset postoperative atrial fibrillation (POAF) within one week of isolated coronary artery bypass grafting (CABG) surgery

    Total number of patients to experience postoperative atrial fibrillation within one week of CABG surgery.

    Time frame: 1 week

Secondary outcomes

  1. Total duration of postoperative atrial fibrillation (POAF) episodes within the first postoperative week

    Duration of postoperative atrial fibrillation episodes will assessed via continuous ECG monitoring and reported in minutes

    Time frame: 1 week

  2. Number of patients with successful stellate ganglion blockade

    Success rate of the stellate ganglion blockade is defined as a ≥1.0°C increase in ipsilateral hand skin temperature from baseline and/or a reduction in skin sympathetic nerve activity (SKNA) as measured by noninvasive surface recordings pre- and post-block.

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • ACRU Study Team · Contact866-265-9263
    • Juan G. Ripoll Sanz, MD · Principal investigator
    • Erica Wittwer, MD,PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 48 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 6, 2026
StartActual
Sep 29, 2026
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
Mayo Clinic in Rochester is now Recruiting
Nov 19, 2026
Start date
Sep 14, 2026→Sep 29, 2026 (actual)
Nov 19, 2026
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedAdults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. Robotic CABG procedures are allowed.
  • EditedCases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if coronary artery bypass grafting (CABG) is listed as the primary intervention with other procedures noted as possible additional interventions.
  • EditedCases will also remain eligible if additional procedures-such as left atrial appendage ligation, MAZE procedure, cryotherapy, or pulmonary vein isolation-are is concomitantly listed with the CABG.
Exclusion criteria
  • ChangedBefore Permanent atrial fibrillationNow History of Permanent atrial fibrillation (paroxysmal, persistent or permanent),
  • RemovedProcedures not requiring cardiopulmonary bypass
  • AddedMAZE procedures, pulmonary vein isolation or cryotherapy will exclude patients if concomitantly listed with the CABG.
Nov 19, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mayo Clinic in Rochester · Rochester, United StatesContact added •••9263Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    Mayo Clinic in Rochester is now Recruiting
    Start date Sep 14, 2026→Sep 29, 2026 (now actual)
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedAdults aged ≥40 years scheduled to undergo isolated coronary artery bypass grafting will be eligible. Robotic CABG procedures are allowed.
    • EditedCases will also remain eligible if, after the initial surgical listing, additional procedures-such as valvular interventions or septal myectomy-are performed, OR if coronary artery bypass grafting (CABG) is listed as the primary intervention with other procedures noted as possible additional interventions.
    • EditedCases will also remain eligible if additional procedures-such as left atrial appendage ligation, MAZE procedure, cryotherapy, or pulmonary vein isolation-are is concomitantly listed with the CABG.
    Exclusion criteria
    • ChangedBefore Permanent atrial fibrillationNow History of Permanent atrial fibrillation (paroxysmal, persistent or permanent),
    • RemovedProcedures not requiring cardiopulmonary bypass
    • AddedMAZE procedures, pulmonary vein isolation or cryotherapy will exclude patients if concomitantly listed with the CABG.
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic in Rochester · Rochester, United StatesContact added •••9263Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07570940
Lead sponsor
Mayo Clinic
Responsible party
Juan Ripoll Sanz (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
May 6, 2026
Start date
Sep 29, 2026
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Anesthesia Clinical Research Unit (ACRU) Study Team
Contact
ripollsanz.juan@mayo.edu
866-265-9263
Juan G. Ripoll Sanz, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion